Table 1 Eligible phase III clinical trials
Study name | Clinical trial number | Diagnosis | Intention | Treatment modality |
|---|---|---|---|---|
ACT | NCT00598156 | Colorectal cancer | Palliative | Kinase inhibitor |
ACT-1 | NCT00646854 | T-cell lymphoma | Curative | Antibody |
BEATRICE | NCT00528567 | Breast cancer | Curative | Antibody |
BRCATrial | NCT00321633 | Breast cancer | Palliative | Chemotherapy |
COMPARZ | NCT00720941 | Renal cell carcinoma | Palliative | Kinase inhibitor |
CYCLUS | NCT00300729 | Non-small cell carcinoma | Palliative | Nonsteroidal anti-inflammatory drug |
ENESTg1 | NCT00785785 | Gastrointestinal stromal tumour | Palliative | Kinase inhibitor |
ESPAC | NCT00058201 | Pancreatic cancer | Curative | Chemotherapy |
EXAM | NCT00704730 | Thyroid cancer | Palliative | Kinase inhibitor |
HYPO-RT-PC | ISRCTN45905321 | Prostate cancer | Curative | Radiation therapy |
INTORSECT | NCT00474786 | Renal cell carcinoma | Palliative | Kinase inhibitor |
MAIN | NCT00486759 | B-cell lymphoma | Curative | Antibody |
OVAR 12 | NCT01015118 | Ovarian cancer | Palliative | Kinase inhibitor |
OVAR 16 | NCT01462890 | Ovarian cancer | Palliative | Antibody |
PALETTE | NCT00753688 | Sarcoma | Palliative | Kinase inhibitor |
PANTHER | NCT00798070 | Breast cancer | Curative | Chemotherapy |
PRELUDE | NCT00332202 | B-cell lymphoma | Curative | Kinase inhibitor |
RASTEN | NCT00717938 | Small cell lung cancer | Palliative | Low molecular heparin |
SOFT | NCT00066690 | Breast cancer | Curative | Endocrine |
SOLD | NCT00593697 | Breast cancer | Curative | Antibody |
SPRINT | NCT00875667 | Mantle cell lymphoma | Palliative | Immune modulator |
START | NCT00409188 | Non-small cell carcinoma | Palliative | Vaccine |
SUN1120 | NCT00676650 | Prostate cancer | Palliative | Kinase inhibitor |